全文获取类型
收费全文 | 174626篇 |
免费 | 923篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 1130篇 |
儿科学 | 6621篇 |
妇产科学 | 2994篇 |
基础医学 | 16391篇 |
口腔科学 | 1531篇 |
临床医学 | 12281篇 |
内科学 | 30604篇 |
皮肤病学 | 658篇 |
神经病学 | 16418篇 |
特种医学 | 8892篇 |
外科学 | 28664篇 |
综合类 | 2308篇 |
预防医学 | 18038篇 |
眼科学 | 2728篇 |
药学 | 9384篇 |
中国医学 | 623篇 |
肿瘤学 | 16285篇 |
出版年
2021年 | 23篇 |
2019年 | 28篇 |
2018年 | 21923篇 |
2017年 | 17365篇 |
2016年 | 19509篇 |
2015年 | 883篇 |
2014年 | 787篇 |
2013年 | 741篇 |
2012年 | 6911篇 |
2011年 | 20947篇 |
2010年 | 18773篇 |
2009年 | 11488篇 |
2008年 | 19437篇 |
2007年 | 21626篇 |
2006年 | 481篇 |
2005年 | 2099篇 |
2004年 | 3304篇 |
2003年 | 4278篇 |
2002年 | 2424篇 |
2001年 | 252篇 |
2000年 | 394篇 |
1999年 | 149篇 |
1998年 | 191篇 |
1997年 | 195篇 |
1996年 | 84篇 |
1995年 | 95篇 |
1994年 | 92篇 |
1993年 | 55篇 |
1992年 | 34篇 |
1991年 | 81篇 |
1990年 | 120篇 |
1989年 | 74篇 |
1988年 | 50篇 |
1987年 | 37篇 |
1986年 | 21篇 |
1985年 | 28篇 |
1984年 | 18篇 |
1983年 | 21篇 |
1982年 | 24篇 |
1980年 | 39篇 |
1974年 | 19篇 |
1970年 | 19篇 |
1969年 | 20篇 |
1939年 | 20篇 |
1938年 | 60篇 |
1937年 | 25篇 |
1935年 | 22篇 |
1934年 | 30篇 |
1932年 | 56篇 |
1930年 | 46篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
11.
Pilar Nicolás 《Hereditary cancer in clinical practice》2007,5(3):144-152
The specific characteristics of genetic data lead to ethical-legal conflicts in the framework of genetic diagnosis. Several international organisations, including UNESCO and the Council of Europe, have enacted rules referring to the use of genetic information. This paper discusses possible legal and ethical criteria that could be used in genetic testing. 相似文献
12.
13.
Sergio Barroilhet Adrián Cano-Prous Salvador Cervera-Enguix Maria João Forjaz Francisco Guillén-Grima 《Social psychiatry and psychiatric epidemiology》2009,44(12):1051-1065
Introduction
This paper presents the results of a study on the psychometric properties of an authorized Spanish version of the McMaster Family Assessment Device, a self-report measure of family functioning. 相似文献14.
15.
16.
Introduction
Although ependymoma is the third most common pediatric brain tumor, we know little about the genetic/epigenetic basis of its initiation, maintenance, or progression. This is due in part to the heterogeneity of the disease, as well as the small sample size of the cohorts analyzed in most studies. 相似文献17.
Peter Angelos 《World journal of surgery》2009,33(4):609-611
18.
Kentaroh Miyoshi Minoru Naito Tsuyoshi Ueno Shinji Hato Hideo Ino 《General thoracic and cardiovascular surgery》2009,57(11):629-632
A benign esophageal leiomyoma with abnormally increased fluorine-18-fluorodeoxyglucose uptake on positron emission tomography
(PET) was resected thoracoscopically. The tumor, of which the maximum standardized uptake value of the lesion was 4.7, was
well defined and 38 mm in diameter. Neither mitotic activity nor degeneration was found histologically; and immunoreactivity
for CD34, CD117, MIB-1, and glucose transporter-1 was negative immunohistochemically. A diagnosis of gastrointestinal stromal
tumor was ruled out by an oncogenic kinase gene mutation study. This case cautions against PET-dependent evaluation for malignant
potential of esophageal submucosal tumors. 相似文献
19.
20.
Statutory reimbursement agencies as well as private insurers throughout member states of the Organization for Economic Cooperation and Development (OECD) reimburse the cost of medicines on the basis of criteria that include robust clinical evidence, budget impact analysis, and incremental cost effectiveness. The Centers for Medicare and Medicaid Services (CMS) in the US are no exception to this rule and are, in principle, seeking to maximize benefit for their Medicare enrollees, whilst ensuring reasonable drug outlays for the small number of drugs that they reimburse. This paper provides a retrospective analysis of the way two functionally equivalent drugs are treated for reimbursement purposes by the CMS; the period under consideration was 2001–3. The two drugs, epoetin-α and darbepoetin-α, are used for the treatment of anemia in renal failure and in patients receiving chemotherapy. By reviewing the publicly available pharmacological and clinical data of epoetin-α and darbepoetin-α, the paper confirms the two drugs’ functional equivalence, despite their structural differences. The implications of dose conversion ratios and costs to Medicare are subsequently explored. It is argued that the issue of dose equivalence between epoetin-α and darbepoetin-α has significant implications for patients, practitioners, and payors. A payor’s perspective is adopted in this respect, whereby clinical evidence and pricing data are used simultaneously. Based on the clinical evidence, a dose conversion ratio for epoetin-α:darbepoetin-α is established, which achieves a comparable clinical effect for the two drugs and this is set to be <254IU:1μg. The incremental costs to Medicare are calculated subsequently. The Average Wholesale Price and the Outpatient Prospective Payment System rule that Medicare uses to reimburse providers are used and suggest that treatment of cancer patients with chemotherapy-related anemia with epoetin-α would save Medicare an estimated $US600 million each year. Patients would also benefit significantly in terms of lower co-payments for epoetin-α. The evidence is supportive of the decision made by the CMS to reimburse the two drugs at the rate reflecting the achievement of comparable clinical effects and therefore reducing the pass-through payments for darbepoetin-α to zero for the 2002–3 fiscal year. 相似文献